SPPI - Spectrum Pharma says poziotinib led to clinically meaningful effect in lung cancer study

Spectrum Pharmaceuticals ([[SPPI]] -1.0%) announced data from an ongoing Phase 2 study for poziotinib in patients with non-small cell lung cancer with EGFR or HER2 exon 20 mutations.The results from the multi-cohort, multi-center study are available in a poster presentation on the website for the 2021 ASCO Annual Meeting.In the three cohorts consisting of 284 patients, one patient in each cohort had a complete intracranial response (8%), the investigators said based on results from 36 patients with brain metastases.The median follow-up for all patients across three cohorts stood at 7.3, 8.3, and 9.2 months, respectively.“These data show clinically meaningful CNS activity for poziotinib treated NSCLC patients with CNS metastases with EGFR or HER2 exon 20 insertion mutations,” noted Francois Lebel, the chief medical officer of Spectrum Pharma.In an update on the ZENITH20 clinical trial in April, the company highlighted the improved tolerability and reduced dose interruption of twice daily ((BID)) poziotinib when compared to

For further details see:

Spectrum Pharma says poziotinib led to clinically meaningful effect in lung cancer study